BioPharma Dive - Latest News

Safety worries spur Pfizer to drop another obesity pill

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it break into the highly lucrative market for obesity drugs.

Apr 14, 2025 - 17:10
 0
Safety worries spur Pfizer to drop another obesity pill

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it break into the highly lucrative market for obesity drugs.

Read More

Tags:

Previous Article

RFK Jr. blasts FDA as industry's 'sock puppet,' warns about 'deep state' influen...

Next Article

Molson Coors CEO Gavin Hattersley to step down

Related Posts

Trump rejects Biden-era plan to let Medicare cover obesity drugs

Trump rejects Biden-era plan to let Medicare cover obes...

Apr 7, 2025  0

Tempero Bio gets $70M to advance substance abuse treatment

Tempero Bio gets $70M to advance substance abuse treatment

Mar 24, 2025  0

Roche halts testing of Sarepta Duchenne gene therapy in Europe

Roche halts testing of Sarepta Duchenne gene therapy in...

Apr 3, 2025  0